Healthcare
Live Price
Offline$158.72
+0.45% today
1Y Change
+60.22%
Window
Jun 20, 2025 → Jun 16, 2026
Coverage: 248 bars · Jun 20, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
UCB S.A. (UCBJY) is a Healthcare stock with a market cap of $43.27B and listed on OTC. The stock last traded around $158.72 and up 60.2% across the available one-year price window (Jun 20, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of +20.9%, EPS growth of +39.9%, a dividend yield of 0.0%. What stands out right now is revenue +20.9%, EPS +39.9%, free cash flow +96.5% with operating margin 25.3% and ROIC 12.1%. Valuation sits in the middle of the pack at P/E 27.7 and price/sales 5.6. Stock Foundry combines UCBJY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
UCBJY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
UCBJY Max Drawdown
-21.77%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for UCBJY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$5.8B
+4.7% YoY
FY Net Income
$1.1B
+153.1% YoY
Free Cash Flow
$1.1B
+41.7% YoY
Revenue Growth
+20.9%
EPS Growth
+39.9%
Gross Margin
74.3%
Net Margin
20.1%
Income statement
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 7.4B | 6.2B | 5.3B | 5.5B | 5.8B |
| Gross Profit | 5.3B | 4.4B | 3.5B | 3.8B | 4.3B |
| Operating Income | 1.1B | 1.3B | 604M | 585M | 1.3B |
| EBITDA | 1.7B | 2.0B | 1.3B | 1.2B | 1.6B |
| Net Income | 1.5B | 1.1B | 343M | 418M | 1.1B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2.3B | 1.6B | 861M | 899M | 1.3B |
| Total Assets | 18.2B | 17.3B | 15.5B | 15.9B | 14.2B |
| Total Liabilities | 7.3B | 7.3B | 6.6B | 6.8B | 5.8B |
| Shareholder Equity | 10.9B | 10.0B | 9.0B | 9.1B | 8.4B |
| Total Debt | 2.2B | 3.0B | 3.0B | 2.9B | 2.1B |
| Net Debt | -6M | 1.5B | 2.2B | 2.0B | 860M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1.6B
+38.8% YoY
Capital Expenditures
493M
-32.9% YoY
Free Cash Flow
1.1B
+41.7% YoY
Key ratios
Gross Margin
74.3%
Operating Margin
25.3%
Net Margin
20.1%
ROE
15.2%
Debt / Equity
0.21x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.